Cassava Sciences Inc - Asset Resilience Ratio
Cassava Sciences Inc (SAVA) has an Asset Resilience Ratio of 11.92% as of March 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cassava Sciences Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2017)
This chart shows how Cassava Sciences Inc's Asset Resilience Ratio has changed over time. See Cassava Sciences Inc (SAVA) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cassava Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cassava Sciences Inc (SAVA) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.10 Million | 11.92% |
| Total Liquid Assets | $2.10 Million | 11.92% |
Asset Resilience Insights
- Moderate Liquidity: Cassava Sciences Inc has 11.92% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Cassava Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Cassava Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Cassava Sciences Inc (2003–2017)
The table below shows the annual Asset Resilience Ratio data for Cassava Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $10.83 Million | -- |
| 2016-12-31 | 10.87% | $2.10 Million | $19.30 Million | +8.38pp |
| 2013-12-31 | 2.49% | $1.25 Million | $50.10 Million | -9.64pp |
| 2012-12-31 | 12.13% | $6.90 Million | $56.86 Million | -13.12pp |
| 2011-12-31 | 25.25% | $24.99 Million | $98.96 Million | -61.88pp |
| 2010-12-31 | 87.13% | $86.43 Million | $99.19 Million | +10.23pp |
| 2009-12-31 | 76.90% | $139.97 Million | $182.00 Million | +57.81pp |
| 2008-12-31 | 19.10% | $36.94 Million | $193.44 Million | -37.98pp |
| 2007-12-31 | 57.08% | $118.50 Million | $207.62 Million | -33.12pp |
| 2006-12-31 | 90.19% | $188.01 Million | $208.46 Million | +35.98pp |
| 2005-12-31 | 54.22% | $117.00 Million | $215.79 Million | -42.64pp |
| 2004-12-31 | 96.86% | $98.02 Million | $101.19 Million | +15.63pp |
| 2003-12-31 | 81.23% | $65.40 Million | $80.51 Million | -- |
About Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known a… Read more